Skip to content

Home
About Polaris
Pipeline
- Expanded Access Program
CDMO
- Genovior Biotech Corp.
Company News
Investors
Contact Us
Q&A

EN
TC
SC

Home
About Polaris
Pipeline
- Expanded Access Program
CDMO
- Genovior Biotech Corp.
Company News
Investors
Contact Us
Q&A

Home
About Polaris
Pipeline
- Expanded Access Program
CDMO
- Genovior Biotech Corp.
Company News
Investors
Contact Us
Q&A

EN
TC
SC

Home
About Polaris
Pipeline
- Expanded Access Program
CDMO
- Genovior Biotech Corp.
Company News
Investors
Contact Us
Q&A

Investors

Company Profile

Group Structure
Organization Chart

Financial Information

Monthly Revenue
Financial Reports
Annual Report

Corporate Governance

Board of Directors
Audit Committee
Compensation Committee
Internal Audit
Corporate Policy
Prevent Insider Trading
Ethical Rule
Information Security

Shareholders’ Area

Major shareholders
Shareholder’s Meeting Information
Investor Conference
TWSE MOPS

Stakeholders’ Area

Stakeholder Contact

Sustainable Development

Sustainable Development Policy

Financial Reports

Q1~Q3 available in Chinese language only

Fiscal Year	Q1	Q2	Q3	Q4
2025		NA	NA	NA
2024
2023
2022

訂閱以獲得我們的最新消息

Email *

Polaris Group is a biopharmaceutical company dedicated to pioneering advanced cancer therapies, primarily focusing on metabolic-related diseases.

P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, KY

Company

About Polaris
Pipeline
Company News
Contact Us
Q&A

CDMO

Genovior Biotech Corporation

Scroll to Top

This site is registered on wpml.org as a development site.